STOCK TITAN

American Shared Hospital Services Q3 loss widens to $620K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

American Shared Hospital Services (AMS) reported third-quarter revenue of $7.624 million, up 6.3% year over year, and nine-month revenue of $23.138 million, up 13.7%. Direct Patient Services revenue rose 13.6% to $4.6 million in the quarter and 27.0% to $13.5 million over nine months; Medical Equipment Leasing revenue was $3.0 million and $9.6 million, respectively.

Net loss attributable to AMS was $620,000 for the quarter and $1.746 million for nine months, compared with $17,000 and $922,000 a year earlier. Adjusted EBITDA was $1.363 million and $3.828 million, compared with $1.944 million and $4.593 million. Nine-month cash from operating activities was $5.8 million; cash, cash equivalents and restricted cash were $9.485 million at September 30, 2026, versus $3.712 million at December 31, 2025. Current portion of long-term debt, net, was $15.7 million.

AMS secured $2.0 million of subordinated financing from RCS/TIG Holdings LLC, an entity controlled by Executive Chairman Ray Stachowiak. AMS expects to upgrade the Gamma Knife system at its Hospital San Javier, S.A. de C.V. joint venture in Guadalajara and expects patient treatments to begin in mid-2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue rose 13.7% to $23.138 million.

Negative

  • Moderate pointThird-quarter attributable net loss widened to $620,000, from $17,000.
  • Moderate pointNine-month Adjusted EBITDA fell to $3.828 million, from $4.593 million.

Filing Explained

AMS reports that it entered into a Third Amendment to its Fifth Third credit agreement and a Forbearance Agreement; in conjunction, it secured $2.0 million in subordinated financing from RCS/TIG, an entity controlled by its Executive Chairman.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $7.624 million Three months ended September 30, 2026; up 6.3% from the third quarter of 2025.
Nine-month revenue $23.138 million Nine months ended September 30, 2026; up 13.7% from the first nine months of 2025.
Third-quarter net loss attributable to AMS $620,000 loss Three months ended September 30, 2026; compared with a $17,000 loss in 2025.
Nine-month net loss attributable to AMS $1.746 million loss Nine months ended September 30, 2026; compared with a $922,000 loss in 2025.
Third-quarter Adjusted EBITDA $1.363 million Three months ended September 30, 2026; compared with $1.944 million in 2025.
Nine-month Adjusted EBITDA $3.828 million Nine months ended September 30, 2026; compared with $4.593 million in 2025.
Cash, cash equivalents and restricted cash $9.485 million At September 30, 2026; compared with $3.712 million at December 31, 2025.
Cash from operating activities $5.8 million First nine months of 2026.
Direct Patient Services technical
"Direct Patient Services segment revenue increased 27.0%"
Gamma Knife Esprit medical
"upgrade of its Peru facility to a Gamma Knife Esprit system"
PBRT medical
"PBRT treatment fractions totaled 960"
Adjusted EBITDA financial
"Adjusted EBITDA for the nine-month period was $3.8 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
restricted cash financial
"Cash, cash equivalents and restricted cash of approximately $9.5 million"
Cash that a company holds but cannot use for day-to-day operations because it is set aside for a specific purpose—such as meeting loan covenants, serving as collateral, funding an escrow, or complying with regulations. Like money in a locked savings account earmarked for a bill, restricted cash reduces the cash available to run the business and pay dividends or debts, so investors treat it differently when assessing a company’s true short-term financial strength.
subordinated financing financial
"secured $2.0 million of subordinated financing"
Debt or credit that ranks below other borrowing from the same borrower for repayment and collateral claims; if the borrower defaults or is liquidated, holders of subordinated financing are paid only after senior creditors are fully satisfied. Subordinated financing can be unsecured or secured behind senior loans, often carries higher interest or fees to compensate for the extra risk, and is governed by a subordination agreement or contractual ranking that determines its place in the repayment order.
Third-quarter revenue $7.624 million Up 6.3% from the third quarter of 2025
Nine-month revenue $23.138 million Up 13.7% from the first nine months of 2025
Third-quarter Direct Patient Services revenue $4.6 million Up 13.6% from the third quarter of 2025
Nine-month Direct Patient Services revenue $13.5 million Up 27.0% from the first nine months of 2025
Third-quarter net loss attributable to AMS $620,000 loss Compared with a $17,000 loss in the third quarter of 2025
Nine-month net loss attributable to AMS $1.746 million loss Compared with a $922,000 loss in the first nine months of 2025
Third-quarter Adjusted EBITDA $1.363 million Compared with $1.944 million in the third quarter of 2025
Nine-month Adjusted EBITDA $3.828 million Compared with $4.593 million in the first nine months of 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did AMS report for Q3 2026?

AMS reported third-quarter revenue of $7.624 million, compared with $7.171 million in Q3 2025, an increase of 6.3%. Direct Patient Services revenue was $4.6 million, up 13.6% from $4.0 million.

How much was AMS's net loss for the first nine months of 2026?

AMS reported a $1.746 million net loss attributable to the company for the first nine months of 2026, compared with $922,000 in 2025; diluted loss per share was $0.26, versus $0.14.

How many radiation therapy procedures did AMS's Rhode Island and Puebla facilities report?

The three Rhode Island radiation therapy facilities and the Puebla, Mexico facility recorded 7,143 procedures in Q3 2026, compared with 7,355. For the first nine months, they recorded 19,788 procedures, compared with 20,401.

How many PBRT treatment fractions did AMS report?

The Proton Beam Radiation Therapy system recorded 960 PBRT treatment fractions in Q3 2026, compared with 1,150 a year earlier. In the first nine months, fractions totaled 3,184, versus 3,095.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000744825 0000744825 2026-11-12 2026-11-12
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): November 12, 2026
 
AMERICAN SHARED HOSPITAL SERVICES
(Exact Name of Registrant as Specified in Its Charter)
 
California
 
1-08789
 
94-2918118
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
   
601 Montgomery Street, Suite 850
San Francisco, California
 
94111
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (415) 788-5300
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
 
Trading Symbol
 
Name of Each Exchange on Which Registered
American Shared Hospital Services Common Stock, No Par Value
 
AMS
 
NYSE AMERICAN
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 2.02. Results of Operations and Financial Condition.
 
On November 12, 2026, the Company issued a press release announcing its financial results for the third quarter and nine-month period ending September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report. The Company does not intend for this exhibit to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,  nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by reference to such filing.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
Description
Exhibit 99.1
Press Release dated November 12, 2026.
104
Cover page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
     
   
AMERICAN SHARED HOSPITAL SERVICES
     
   
(Registrant)
     
Dated: November 12, 2026
 
/s/ Raymond C. Stachowiak
     
   
By: Raymond C. Stachowiak
     
   
Title: Executive Chairman of the Board
 
 

Exhibit 99.1

 

 

American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results

 

Third Quarter Revenue Increased 6% to $7.6 Million; Direct Patient Services Revenue Increased 14%

 

Nine-Month Revenue Increased 14% to $23.1 Million; Direct Patient Services Revenue Increased 27%

 

Generated $5.8 Million in Cash from Operating Activities During the First Nine Months of 2026

 

Cash, Cash Equivalents and Restricted Cash Increased to approximately $9.5 million

 

Conference Call Scheduled for Today at 12:00 PM ET

 

 

SAN FRANCISCO, Calif., November 12, 2026 – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, today announced financial results for the third quarter and nine months ended September 30, 2026.

 

Craig Tagawa, Interim Chief Executive Officer, commented, “During the third quarter, we continued to make progress in growing our Direct Patient Services business, with revenue in this segment increasing 14% year over year. For the first nine months of 2026, total revenue increased 14%, driven by continued growth in our Rhode Island radiation therapy operations and higher procedure volumes at our international Gamma Knife facilities. While we continue to optimize our cost structure, we remain focused on improving operational performance, managing expenses, and maximizing the contribution of our existing facilities. We are also continuing to advance initiatives intended to strengthen our financial position and support the Company's operations. Additionally, we are pleased to report the $5.8 million in cash flow generated year to date and the subsequent increase in our overall cash balances. Overall, we are pleased with the progress we are making and remain keenly focused on enhancing our overall performance and shareholder value.”

 

Ray Stachowiak, Executive Chairman, stated, “We continue to focus on positioning the Company for long-term success by building on our established presence in radiation oncology and pursuing opportunities to expand the reach and capabilities of our technology and services. We believe our combination of specialized treatment capabilities, experienced operating teams, and relationships with leading healthcare institutions provides a foundation from which to create additional value. Additionally, our joint venture initiative with Hospital San Javier in Guadalajara, Mexico, represents an important opportunity to extend our Gamma Knife presence into another market. Our broader priority remains focused on the disciplined management of our assets, strengthening our financial foundation, and pursuing strategic opportunities that can contribute to sustainable long-term growth and shareholder value.”

 

 

 

Third Quarter 2026 Results

 

Total revenue for the third quarter of 2026 increased 6.3% to $7.6 million, compared with $7.2 million in the third quarter of 2025. Growth was driven by the Company's Direct Patient Services segment, partially offset by a modest decline in Medical Equipment Leasing revenue.

 

Direct Patient Services segment revenue increased 13.6% to $4.6 million, compared with $4.0 million in the prior-year period. Revenue from the Company's three Rhode Island radiation therapy facilities and its Puebla, Mexico facility increased 13.5% to $3.3 million, compared with $2.9 million in the third quarter of 2025. Radiation therapy procedures at these facilities totaled 7,143, compared with 7,355 in the prior-year quarter.

 

Within the Company's international Gamma Knife operations in Peru and Ecuador, procedure volume increased 8.9% period over period. The Company completed the upgrade of its Peru facility to a Gamma Knife Esprit system in June 2025. The upgraded system provides shorter treatment times, which has helped support increased procedure volume.

 

Medical Equipment Leasing segment revenue was $3.0 million, compared with $3.1 million in the third quarter of 2025, a decrease of 3.1%. Within this segment, revenue generated through the Company’s Proton Beam Radiation Therapy (“PBRT”) system was $2.0 million, compared with $2.1 million in the prior-year quarter. PBRT treatment fractions totaled 960, compared with 1,150 in the third quarter of 2025. The Company believes fluctuations in PBRT treatment volume reflect normal cyclical changes in patient activity. The Company's domestic Gamma Knife operations also contributed to leasing revenue, with domestic Gamma Knife procedure volume increasing 13.1% compared with the prior-year quarter.

 

Gross profit for the third quarter was $1.5 million, compared with $1.6 million in the prior-year period. Total costs of revenue increased to $6.1 million from $5.6 million. The increase reflected higher operating costs at the Rhode Island and international Gamma Knife facilities.

 

Selling and administrative expenses increased to $1.8 million from $1.5 million in the third quarter of 2025. The increase primarily reflected legal, banking and consulting expenses associated with the Third Amendment to the Credit Agreement with Fifth Third Bank, executed in July 2026.

 

 

 

The Company reported a net loss attributable to American Shared Hospital Services of $620,000, or $0.09 per diluted share, compared with a net loss of $17,000, or $0.00 per diluted share, in the third quarter of 2025.

 

Third quarter adjusted EBITDA was $1.4 million compared to $1.9 million in the prior year quarter.

 

Nine-Month 2026 Results

 

For the first nine months of 2026, total revenue increased 13.7% to $23.1 million, compared with $20.4 million in the first nine months of 2025. Growth was driven primarily by the Company's Direct Patient Services segment, reflecting higher revenue from its Rhode Island and Puebla radiation therapy operations and increased procedure volume at its international Gamma Knife facilities.

 

Direct Patient Services segment revenue increased 27.0% to $13.5 million, compared with $10.7 million in the prior-year period. Revenue from the Company's three Rhode Island radiation therapy facilities and its Puebla, Mexico facility increased to approximately $9.6 million, compared with $7.8 million in the first nine months of 2025. Radiation therapy procedures at these facilities totaled 19,788, compared with 20,401 in the prior-year period.

 

At the Company's international Gamma Knife facilities in Peru and Ecuador, procedure volume increased 30.7% compared with the first nine months of 2025. The increased volume reflects, in part, the benefits of the Gamma Knife Esprit upgrade completed at the Peru facility in June 2025, which shortened treatment times and improved capacity.

 

Medical Equipment Leasing segment revenue was $9.6 million, compared with $9.7 million in the first nine months of 2025, a decrease of approximately 1.0%. PBRT revenue increased to $6.3 million from $5.7 million in the prior-year period. PBRT treatment fractions totaled 3,184, compared with 3,095 in the first nine months of 2025. The increase in PBRT revenue despite relatively modest procedure growth reflected higher average reimbursement. Domestic Gamma Knife procedure volume was lower than the prior-year period, primarily due to the expiration of one customer contract in April 2025.

 

Gross profit for the first nine months of 2026 was consistent with the prior-year period of $4.2 million. Total costs of revenue increased to $18.9 million from $16.2 million, reflecting higher operating costs, including, credit loss reserves, partially offset by lower depreciation and amortization.

 

Selling, general and administrative expenses increased to $5.8 million from $5.1 million in the first nine months of 2025, primarily reflecting higher legal, banking and consulting expenses associated with the Third Amendment to the Credit Agreement with Fifth Third Bank entered into in July 2026.

 

 

 

The Company reported a net loss attributable to American Shared Hospital Services of $1.7 million, or $0.26 per diluted share, compared with a net loss of $922,000, or $0.14 per diluted share, in the first nine months of 2025.

 

Adjusted EBITDA for the nine-month period was $3.8 million compared to $4.6 million in the prior year period.

 

Balance Sheet Highlights

 

At September 30, 2026, the Company had cash, cash equivalents and restricted cash of approximately $9.5 million compared with $3.7 million at December 31, 2025.

 

For the first nine months of 2026, the Company generated $5.8 million in cash from operating activities, compared with $3.8 million in the same period of 2025. Cash used in investing activities was approximately $175,000, while cash provided by financing activities was approximately $141,000.

 

The current portion of long-term debt, net was $15.7 million as of September 30, 2026, representing a decrease from $17.3 million at December 31, 2025.

 

Shareholders’ equity attributable to American Shared Hospital Services, excluding non-controlling interests, was $22.6 million, or approximately $3.40 per share, based on 6.65 million shares outstanding at September 30, 2026. This reflects the Company’s equity position after accounting for the net loss during the period and the interests of non-controlling shareholders in certain operating subsidiaries, including the Rhode Island facilities and international operations.

 

As previously disclosed during the third quarter, the Company entered into a Third Amendment to its Credit Agreement and Forbearance Agreement with Fifth Third Bank. In conjunction with the amendment, the Company secured $2.0 million of subordinated financing from RCS/TIG Holdings LLC, an entity controlled by the Company's Executive Chairman. The financing is intended to provide additional liquidity as the Company continues to execute its strategic initiatives.

 

Management believes the third quarter financing and the agreement reached with Fifth Third Bank actions provide additional flexibility while the Company continues exploring longer-term capital structure alternatives designed to support future growth initiatives and strengthen its balance sheet.

 

San Javier Joint Venture

 

The Company is continuing to advance its joint venture with Hospital San Javier, S.A. de C.V. in Guadalajara, Mexico. AMS expects to upgrade the hospital's existing Gamma Knife Perfexion system to a Gamma Knife Esprit system and expects patient treatments at the facility to begin in mid-2027. The San Javier initiative represents a potential opportunity to extend AMS's Gamma Knife presence into another market and expand its international Direct Patient Services platform.

 

 

 

Strategic Growth Initiatives

 

"Our strategy remains focused on building a differentiated platform of advanced radiation therapy technologies and services that address the growing demand for precision cancer treatment," said Ray Stachowiak, Executive Chairman. "Our combination of Gamma Knife, Proton Beam Radiation Therapy and direct patient services provide the Company with multiple opportunities to expand our geographic reach, increase treatment volumes and drive long-term growth. We believe our diversified platform and established healthcare partnerships provide a strong foundation for capitalizing on these opportunities.”

 

"As we continue to evaluate our capital structure strategies, our underlying operating business is demonstrating encouraging progress. During the first nine months of 2026, we achieved 14% revenue growth, driven by a 27% increase in Direct Patient Services revenue, reflecting higher treatment volumes and continued progress across several of our facilities. We are also encouraged by the continued development of our international operations and the cash generated by the business.”

 

"Our priorities remain focused on improving operational performance, increasing utilization across our existing network, expanding access to advanced radiation therapy services and strengthening our financial position. We remain committed to disciplined capital allocation and believe that continued execution of these initiatives positions the Company for sustainable long-term shareholder value."

 

Conference Call

 

The Company will hold a conference call to discuss its third quarter financial results today at 12:00 pm ET.

 

Teleconference and Webcast Information

 

To participate, domestic callers may dial 1-844-413-3972 and international callers may dial 1-412-317-5776 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.

 

A simultaneous webcast of the call may be accessed through the Company's website, www.ashs.com or directly:

 

https://event.choruscall.com/mediaframe/webcast.html?webcastid=nqCysq92

 

A replay of the call will be available at 1-855-669-9658 or 1-412-317-0088, access code 6458694, through November 19, 2026. The call will also be available for replay on the Company’s website at www.ashs.com.

 

 

 

About American Shared Hospital Services (NYSE American: AMS)

 

American Shared Hospital Services (AMS) is a leading provider of turnkey solutions to cancer treatment centers, health systems, and cancer networks in North and South America. The Company works closely with its partners to develop and grow their cancer service lines and provide integrated cancer care to patients in a convenient local setting close to home. For centers under health system partnerships, the Company and its health system partners share in the capital investment cost and profitability of the operations based on their respective ownership interests. For more information, please visit: www.ashs.com

 

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton beam radiation therapy and direct patient care services business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risk of compliance with debt covenants, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton beam radiation therapy and direct patient care services businesses, the risks of changes to Centers for Medicare & Medicaid Services reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, PBRT, and direct patient care services businesses, the risk of expanding within or into new markets, the risk that the continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports filed by the Company with the Securities and Exchange Commission.

 

Non-GAAP Financial Measure

 

Adjusted EBITDA, the non-GAAP measure presented in this press release and supplementary information, is not a measure of performance under the accounting principles generally accepted in the United States ("GAAP"). This non-GAAP financial measure has limitations as an analytical tool, including that it does not have a standardized meaning. When assessing our operating performance, this non-GAAP financial measure should not be considered a substitute for, and investors should also consider, income before income taxes, income from operations, net income attributable to the Company, earnings per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability.

 

 

 

EBITDA is a non-GAAP financial measure representing our earnings before interest expense, interest income, income tax expense (benefit), depreciation, and amortization. We define Adjusted EBITDA as net loss before interest expense, interest income, income tax expense (benefit), depreciation and amortization expense, and stock-based compensation expense.

 

We use this non-GAAP financial measure as a means to evaluate period-to-period comparisons. Our management believes that this non-GAAP financial measure provides meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as stock-based compensation expense. We believe that both management and investors benefit from referring to this non-GAAP financial measure in assessing our performance.

 

Contacts

American Shared Hospital Services
Ray Stachowiak, Executive Chairman
rstachowiak@ashs.com

 

Investor Relations

Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com

 

 

 

American Shared Hospital Services

Condensed Consolidated Statements of Operations

 

 

   

Summary of Operations Data

 
           

(Unaudited)

         
                                 
   

Three months ended September 30,

   

Nine months ended September 30,

 
                                 
   

2026

   

2025

   

2026

   

2025

 

Revenues

  $ 7,624,000     $ 7,171,000     $ 23,138,000     $ 20,354,000  

Costs of revenue

    6,105,000       5,585,000       18,898,000       16,196,000  

Gross margin

    1,519,000       1,586,000       4,240,000       4,158,000  

Selling and administrative expense

    1,803,000       1,538,000       5,755,000       5,092,000  

Interest expense

    480,000       392,000       1,083,000       1,253,000  

Operating loss

    (764,000 )     (344,000 )     (2,598,000 )     (2,187,000 )

Interest and other income

    21,000       63,000       122,000       172,000  

Loss before income taxes

    (743,000 )     (281,000 )     (2,476,000 )     (2,015,000 )

Income tax expense (benefit)

    163,000       48,000       390,000       (296,000 )

Net loss

    (906,000 )     (329,000 )     (2,866,000 )     (1,719,000 )

Less: Net loss attributable to non-controlling interests

    286,000       312,000       1,120,000       797,000  

Net loss attributable to American Shared Hospital Services

  $ (620,000 )   $ (17,000 )   $ (1,746,000 )   $ (922,000 )
                                 

Loss per common share:

                               

Basic

  $ (0.09 )   $ (0.00 )   $ (0.26 )   $ (0.14 )

Diluted

  $ (0.09 )   $ (0.00 )   $ (0.26 )   $ (0.14 )
                                 

Weighted Average Shares Outstanding:

                               

Basic

    6,773,000       6,632,000       6,748,000       6,593,000  

Diluted

    6,773,000       6,632,000       6,748,000       6,593,000  

 

 

 

American Shared Hospital Services

Balance Sheet Data

 

 

   

Balance Sheet Data

 
   

(Unaudited)

 
                 
   

9/30/2026

   

12/31/2025

 

Cash, cash equivalents and restricted cash

  $ 9,485,000     $ 3,712,000  

Current assets

  $ 19,059,000     $ 17,720,000  

Total assets

  $ 52,865,000     $ 55,479,000  
                 

Current liabilities

  $ 23,627,000     $ 23,444,000  

Shareholders' equity American Shared Hospital Services

  $ 22,608,000     $ 24,034,000  
                 

Outstanding shares

    6,650,000       6,575,000  

 

 

 

American Shared Hospital Services

Adjusted EBITDA

 

 

     

Reconciliation of GAAP to Non-GAAP Adjusted Results

 
             

(Unaudited)

         
                                   
     

Three months ended September 30,

   

Nine months ended September 30,

 
     

2026

   

2025

   

2026

   

2025

 

Net loss attributable to American Shared Hosptial Services

  $ (620,000 )   $ (17,000 )   $ (1,746,000 )   $ (922,000 )

Less (plus):

Income tax expense (benefit)

    163,000       48,000       390,000       (296,000 )
 

Interest expense

    480,000       392,000       1,083,000       1,253,000  
 

Interest income

    (40,000 )     (34,000 )     (122,000 )     (157,000 )
 

Depreciation and amortization expense

    1,342,000       1,454,000       3,982,000       4,411,000  
 

Stock-based compensation expense

    38,000       101,000       241,000       304,000  

Adjusted EBITDA

  $ 1,363,000     $ 1,944,000     $ 3,828,000     $ 4,593,000  

 

 

Filing Exhibits & Attachments

5 documents

Keep reading